FDA Reverses Course, Officially Classifies NMN as Legal Dietary Supplement
FDA reverses 2022 decision, allowing NMN to be sold as a dietary supplement after industry and scientific community pushback.
-
-
European Medicines Agency Declares Testosterone Therapy Cardiovascular-Safe Based on TRAVERSE Follow-Up
EMA declares testosterone therapy cardiovascular-safe based on extended TRAVERSE trial data showing no increased heart risk.
-
FDA Removes Black Box Warning From Hormone Replacement Therapy After 20+ Years
FDA removes black box warning from hormone replacement therapy after 20+ years, reflecting evolving understanding of treatment risks.
-
Major Research Peptide Firm Ceases Operations Amid Regulatory Pressure
A major research peptide supplier has closed after regulatory pressure, signaling intensified FDA enforcement in the sector.
-
HHS Under RFK Jr. Reverses FDA Peptide Restrictions, BPC-157 and Thymosin Alpha-1 Return to Market
HHS reverses FDA restrictions on BPC-157 and thymosin alpha-1, returning controversial peptides to market under Kennedy’s leadership.
-
Tirzepatide Reduces Heart Failure Events by 38% in Landmark SUMMIT Trial
New SUMMIT trial data shows tirzepatide cut heart failure events by 38% in patients with preserved ejection fraction and obesity.
-
Large Study Finds No Thyroid Cancer Link to GLP-1 Medications, Easing Safety Concerns
Study of 145,000 patients found no increased thyroid cancer risk from GLP-1 drugs, easing longstanding safety concerns.
-
Study Raises Concerns About Bone Density Loss in Patients on Long-Term Semaglutide
New research shows long-term semaglutide use linked to bone density decline beyond typical weight loss effects.
-
Eli Lilly’s Orforglipron Outperforms Oral Semaglutide in Head-to-Head Weight Loss Trial
New trial shows Eli Lilly’s oral weight loss drug orforglipron beats oral semaglutide in direct comparison study.
-
Medicare Part D Now Covers GLP-1 Medications for Obesity in Historic Policy Shift
CMS announces Medicare Part D will now cover GLP-1 medications for obesity, ending decades-old exclusion for weight loss drugs.
